Prostate Risk and Monitoring During Testosterone Replacement Therapy.
Shalender BhasinIan M ThompsonPublished in: The Journal of clinical endocrinology and metabolism (2024)
Testosterone treatment of men with hypogonadism, screened to exclude those at high risk of prostate cancer, is associated with low risk of adverse prostate events. Baseline evaluation of prostate cancer risk and a standardized monitoring plan can minimize the risk of unnecessary prostate biopsy while enabling the detection of high-grade prostate cancers in men receiving TRT.